Improving cancer immunotherapy with DNA methyltransferase inhibitors

Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial. Recent findings suggest...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 2016-07, Vol.65 (7), p.787-796
Main Authors: Saleh, Mohammad H., Wang, Lei, Goldberg, Michael S.
Format: Article
Language:English
Subjects:
Animals
Cancer Research
DNA Methylation - drug effects
DNA Methylation - immunology
DNA Modification Methylases - antagonists & inhibitors
DNA Modification Methylases - immunology
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Focussed Research Review
Humans
Immunology
Immunotherapy - methods
Medicine
Medicine & Public Health
Neoplasms - enzymology
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - therapy
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial. Recent findings suggest that epigenetic modifying drugs can prime antitumor immunity by increasing expression of tumor-associated antigens, chemokines, and activating ligands by cancer cells as well as cytokines by immune cells. This review, drawing from both preclinical and clinical data, describes some of the mechanisms of action that enable DNA methyltransferase inhibitors to facilitate the establishment of antitumor immunity.
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-015-1776-3